P1076 - A NOVEL PROGNOSTIC SCORE COMBINING SARCOPENIA AND LABORATORY MARKERS FOR GASTRIC CANCER

P1076

A NOVEL PROGNOSTIC SCORE COMBINING SARCOPENIA AND LABORATORY MARKERS FOR GASTRIC CANCER

Y. Xue^1,*, H. Zhang¹, Z. Zheng¹, X. Liu¹, J. Yin¹, J. Zhang¹

¹Beijing Friendship Hospital, Capital Medical University, Beijing, China

Rationale: Nutritional immune status is an important yet underexplored factor influencing the prognosis of gastric cancer (GC) patients. This study aimed to assess the relationship between preoperative nutritional immune-inflammatory status and the short- and long-term outcomes of GC patients undergoing radical gastrectomy, with the goal of developing a predictive tool for identifying high-risk patients and improving personalized treatment.

Methods:  A retrospective analysis was conducted on clinical data from GC patients who underwent radical total gastrectomy (TG) at Beijing Friendship Hospital, Capital Medical University, between September 2016 and September 2023. Preoperative skeletal muscle index (L3SMI) was combined with laboratory parameters to evaluate prognostic significance. Kaplan-Meier curves and multivariate Cox regression were used for survival analysis.

Results: Preoperative sarcopenia (SMI <39.11 cm²/m² for men, <27.17 cm²/m² for women), lymphocyte count, and platelet levels were independent risk factors for overall survival (OS) and progression-free survival (PFS). A novel scoring system was developed: sarcopenia (1 point), platelet-to-lymphocyte ratio (PLR) ≥98.91 (1 point), and PLR <98.91 (0 points). The three-year OS rates for low-risk (93.9%), medium-risk (75.2%), and high-risk (57.8%) groups differed significantly (p = 0.013), with corresponding PFS rates of 88.3%, 72.0%, and 63.3% (p = 0.025). The scoring system showed superior predictive accuracy for 3-year OS (AUC = 0.679) compared to conventional markers like the CONUT, PNI, and SII scores (all p < 0.05).

Conclusion: Preoperative nutritional immune-inflammatory status significantly influences prognosis in GC patients undergoing radical TG. The developed scoring system, combining L3SMI and laboratory markers, effectively predicts survival and aids in personalized treatment decisions.

Disclosure of Interest: None declared